Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer
May 29, 2018
Remote Monitoring Can Reduce Radiation-Related Symptoms in Head and Neck Cancer
May 30, 2018
Despite USPSTF Recommendations, Lung Screening Rates Low Among Heavy Smokers
May 31, 2018
Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers
June 01, 2018
Dr Leonard B. Saltz on Deciding When a Patient Should Receive NGS Testing
June 02, 2018
Promising Early Phase Results With bb2121 CAR T Treatment in Relapsed Refractory Multiple Myeloma
June 02, 2018
Dr Peter Paul Yu Discusses the Impact of Health Information Technology in Oncology
June 02, 2018
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
June 02, 2018
Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine
June 02, 2018
Ellen Miller Sonet Highlights Financial Burdens of Patients With Cancer
June 02, 2018
Utilization Management in Oncology: Current Strategies and a Path Forward
June 02, 2018
Immune Checkpoint Inhibitors Improve Outcomes in Mismatch Repair Deficient CRC, but Can Induce irAEs
June 02, 2018
ZUMA-1: Response to Axi-cel at Three Months Prognostic for Remission in B-cell Lymphoma
June 03, 2018
Cetuximab With Chemoradiation Worse Than Chemoradiation Alone in Older Patients With HNSCC
June 03, 2018
Dr Michael Thompson: The Role of Precision Medicine in the Community Setting
June 03, 2018
Dr Victoria Villaflor Outlines Challenges With Pursuing Precision Medicine
June 03, 2018
Clinical Trials: Sharing the Road With Real-World Evidence
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
Nearly Half of Patients With Metastatic CSCC Respond to Cemiplimab, on Fast Track at FDA
June 04, 2018
Currently Reading
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018

Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC

Mary Caffrey
Researchers are examining combination therapies with immunotherapy, with and without chemotherapy.
Combination treatments involving checkpoint inhibitors continue to gain attention, including both combinations involving more than 1 immunotherapy and those that involve immunotherapy and chemotherapy. Researchers continue to seek biomarkers that will allow them to match treatment combinations with patients who will most benefit.

On Monday, Bristol-Myers Squibb followed up on results it released earlier this year from the phase 3 Checkmate 227 trial in non-small cell lung cancer (NSCLC); it previously presented results from the nivolumab (Opdivo) and ipilimumab (Yervoy) combination, which showed that this combination reduced progression risk 42% for patients with a high tumor mutation burden.

Results presented at the American Society of Clinical Oncology (ASCO) involve patients in the trial arm treated with nivolumab and chemotherapy. Researchers report results for 550 chemotherapy-naïve patients with stage IV or recurrent NSCLC; they had no known EGFR/ALK mutations, and had < 1% PD-L1 expression. These included 177 in the nivolumab plus chemotherapy arm, compared with 186 who were treated with chemotherapy only.

Those taking the nivolumab-chemotherapy arm had improved progression-free survival (PFS) over the chemotherapy arm (hazard ratio = 0.74; CI, 0.58-0.94). Minimum follow-up was 11.2 months, and patients were treated up to 2 years. Most subgroups saw PFS with the nivolumab-chemotherapy combination, but the benefit was more pronounced among non-squamous (HR = 0.68) than among squamous (HR = 0.92).

The rates of adverse events that caused patients to stop taking therapy were about the same in both the nivolumab-chemotherapy arm (13%) and the chemotherapy arm (14%).

Reference

Borghaei H, Hellman MD, Paz-Ares LG, et al. Nivolumab + platinum doublet chemotherapy vs chemo as first-line treatment for advanced non-small cell lung cancer (NSCLC) with < 1% tumor PD-L1 expression. J Clin Oncol 2018; 36 (suppl; abstr 9001).

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!